Affymetrix Exclusively Licenses Technology from Peptide Groove LLP for HLA Typing from Genotyping Data
October 20 2014 - 6:30AM
Business Wire
Affymetrix (NASDAQ:AFFX) announced today that it has exclusively
licensed technology from Peptide Groove LLP that enables HLA typing
of human samples from genotyping data generated from a variety of
assays including the company's Axiom® genotyping assays. The
partners at Peptide Groove LLP developed HLA*IMP, the first HLA
typing statistical imputation method which can call 4-digit HLA
types from SNP genotyping data with high accuracy. Conventional
methods for HLA typing, such as DNA sequencing, can be laborious,
time consuming, and expensive. Imputing HLA types from genotyping
data, such as those from Affymetrix’ Axiom genotyping platform,
offers a new, very high-throughput, and low-cost approach.
The technology will enable purpose-built, highly efficient HLA
typing screening arrays that could prove useful for a broad range
of HLA typing application needs, including donor repositories, drug
development clinical trials, and many translational research
studies. Additionally, customers using Affymetrix Axiom biobank
arrays and other genotyping arrays for GWAS and fine mapping will
be able to ascertain HLA type information without further
experimentation.
“We now have a method for inferring an individual's HLA genotype
based on evaluating genetic information from nearby variable sites
that are more easily assayed than conventional HLA markers,” stated
Peter Donnelly, Professor of Statistical Science and Director of
the Wellcome Trust Centre for Human Genetics at the University
of Oxford and co-founder of Peptide Groove LLP. “Better imputation
of classical HLA alleles is an important goal in enabling
association studies to understand the genetic risk of many complex
and infectious diseases.”
“Determining HLA genotypes is an important part of many studies
to understand the genetic basis of disease risk,” said Andy Last,
Chief Operating Officer of Affymetrix. “The ability to determine
HLA types from new or pre-existing genotyping data in parallel with
other genetic analyses is a combination that will enable new
scientific insights with greater efficiency.”
Affymetrix plans to incorporate the licensed technology as an
added capability accompanying its genotyping products including
Axiom Genotyping Solution.
PLEASE NOTE: Affymetrix, the Affymetrix logo,
Axiom, and all other trademarks are the property
of Affymetrix, Inc. All other trademarks are the property
of their respective owners.
About Peptide Groove LLP
Peptide Groove LLP is an Oxford, UK, based partnership focused
on developing and commercializing sophisticated statistical
analysis tools for high-throughput genotyping data in a range
of biomedical applications. The partners of Peptide Groove, Gil
McVean, Peter Donnelly, Stephen Leslie, and Alexander Dilthey, are
international research leaders in statistical genetics and
genomics.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness. The
Company provides leadership and support, partnering with customers
in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes
in their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
65,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, Ohio,
San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2013, and other SEC reports for subsequent
quarterly periods.
AffymetrixMedia Contact:Mindy Lee-Olsen, 408-731-5523Vice
President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor Contact:Doug
Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024